Cerus Corporation Projects 9% to 11% Revenue Growth in 2026, with Intercept Fibrinogen Complex Anticipated to See 20% to 30% YoY Revenue Boost.

Cerus Corporation (CERS) projects a 9-11% increase in product revenue for 2026, with Intercept Fibrinogen Complex (IFC) revenue expected to rise 20-30% YoY. The company's financial health is characterized by a revenue of $199.19 million, a gross margin of 55.19%, and a net margin of -8.01%. However, Cerus displays a high debt-to-equity ratio of 1.6 and an Altman Z-Score of -4.21, placing it in the distress zone. Valuation metrics show a P/S ratio of 1.95 and a P/B ratio of 6.42, close to their 1-year highs. Analyst targets suggest a potential upside from current levels.